<DOC>
	<DOCNO>NCT00431704</DOCNO>
	<brief_summary>The purpose study evaluate activity safety combination vinorelbine , carboplatin trastuzumab HER2-positive metastatic breast cancer .</brief_summary>
	<brief_title>VinCaT : Vinorelbine , Carboplatin Trastuzumab Advanced Her-2 Positive Breast Cancer</brief_title>
	<detailed_description>The addition trastuzumab chemotherapy contain anthracyclines taxanes improve survival patient Her-2 positive metastatic breast cancer , new combination less toxicity cross resistance need . Early clinical study suggest combination vinorelbine , carboplatin trastuzumab active metastatic breast cancer , less toxicity . In phase II single center trial , 39 patient enrolled evaluate activity safety combination .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histological cytological diagnosis breast cancer Stage IV disease None one prior treatment metastatic disease ( prior treatment trastuzumab metastatic disease permit ) Overexpression HER2 ( immunohistochemistry 3+ ) genetic amplification cerbB2/neu ( FISH+ ) ECOG Performance Status 02 Age &gt; 18 &lt; 75 year Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % Life expectancy &gt; 3 month Signed informed consent Absence measurable evaluable disease Life expectancy &lt; 3 month ECOG performance status &gt; 2 History prior malignancy last 5 year ( adequately treat nonmelanoma skin cancer excise cervical carcinoma situ ) . Previous chemotherapy vinorelbine carboplatin ( adjuvant therapy metastatic disease ) Previous therapy trastuzumab metastatic disease ( previous adjuvant therapy trastuzumab permit ) Neutrophil &lt; 2000/mm3 , platelet &lt; 100,000/mm3 , haemoglobin &lt; 9 g/dl Creatinine &gt; 1.5 x upper normal limit GOT and/or GPT &gt; 2.5 x upper normal limit and/or Bilirubin &gt; 1.5 x upper normal limit absence hepatic metastasis GOT and/or GPT &gt; 5 x upper normal limit and/or Bilirubin &gt; 3 x upper normal limit presence hepatic metastasis Congestive hearth failure history congestive heart failure , unstable angina pectoris even medically control , myocardial infarction , clinically significant valve disease , uncontrolled arrhythmia Any concomitant pathology would , investigator 's opinion , contraindicate use drug study Male gender Pregnant lactate woman Refusal incapacity provide inform consent Inability comply follow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>advanced</keyword>
	<keyword>her-2 positive</keyword>
</DOC>